One of the mechanisms behind chemoresistance is the treat-ments, in particular, to chemotherapy (chemoresistance). Functional evidence for enhanced MDR of TICs was previously provided using a “side population” assay. This assay estimates MDR capacity by a single parameter - cell’s ability to retain fluorescent MDR substrate, so that cells with high MDR capacity (“side population”) demonstrate low substrate retention. In the present work MDR in TICs was investigated in greater detail using a kinetic approach, which monitors MDR efflux from single cells. Analysis of kinetic traces obtained allowed for the estimation of both the velocity ($V_{max}$) and affinity ($K_{m}$) of MDR transport in single cells. In this way it was shown that activation of MDR in TICs occurs in two ways: through the increase of $V_{max}$ in one fraction of cells, and through decrease of $K_{m}$ in another fraction. In addition, kinetic data showed that heterogeneity of MDR parameters in TICs significantly exceeds that of bulk cells. Potential consequences of these findings for chemotherapy are discussed.

## Abstract

Multidrug resistance (MDR) driven by ABC (ATP binding cassette) membrane transporters is one of the major causes of treatment failure in human malignancy. MDR capacity is thought to be unevenly distributed among tumor cells, with higher capacity residing in tumor-initiating cells (TIC) (though opposite finding are occasionally reported). Functional evidence for enhanced MDR of TICs was previously provided using a “side population” assay. This assay estimates MDR capacity by a single parameter - cell’s ability to retain fluorescent MDR substrate, so that cells with high MDR capacity (“side population”) demonstrate low substrate retention. In the present work MDR in TICs was investigated in greater detail using a kinetic approach, which monitors MDR efflux from single cells. Analysis of kinetic traces obtained allowed for the estimation of both the velocity ($V_{max}$) and affinity ($K_{m}$) of MDR transport in single cells. In this way it was shown that activation of MDR in TICs occurs in two ways: through the increase of $V_{max}$ in one fraction of cells, and through decrease of $K_{m}$ in another fraction. In addition, kinetic data showed that heterogeneity of MDR parameters in TICs significantly exceeds that of bulk cells. Potential consequences of these findings for chemotherapy are discussed.

## Introduction

One of the most important aspects of tumor heterogeneity is the existence of tumor-initiating cells (TICs) responsible for both the initiation of cancers and dissemination of metastases [1,2]. Besides their elevated proliferative and invasive capacity, these cells also demonstrate high resistance to antican-cer treatments, in particular, to chemotherapy (chemoresistance). One of the mechanisms behind chemoresistance is the overexpression of plasma membrane pumps (ABC transporters) which expel chemotherapeutics from the cell interior [3]. The overall functional characterization of MDR in TICs to date has been provided by a widely used flow cytometric side population assay. This assay is based on the differential accumulation of a fluorescent MDR substrate, Hoechst 33342, in cancer cells. Specifically, the cells exhibiting low Hoechst retention are considered as having high MDR capacity and referred to as the “side population”[4].

Intracellular dye retention is a complex parameter reflecting, on one hand, cellular dye uptake and, on the other hand, turnover and affinity of the dye efflux system. A more detailed quantitative characterization of MDR transport in TICs requires the determination of its kinetic transport parameters ($V_{max}$ and $K_{m}$) and transport efficiency ($V_{max}/K_{m}$). Such a study is of particular importance, since besides expressional regulation, MDR transporters are subject to functional modulation, for instance, by a transporter’s membrane environment and the cellular metabolic state. For example, the reported controversy on the relation between a cell’s tumor-initiating ability and its chemoresistance [5,6] might be caused by multifactorial regulation of MDR transport kinetics in different cell subpopulations. A detailed kinetic characterization of MDR function in TICs is increasingly important in light of the fact that elevated chemoresistance of TICs may result in the increase of TIC fraction and subsequent malignancy in the residual cancer after chemotherapy [7,8].

The aim of this work was the kinetic characterization of MDR in TICs in comparison to MDR in bulk tumor cells. As an experimental object of this work we used the intrinsic MDR capacity of naïve (not exposed to MDR-inducing therapeutics) MCF-7 and 4T1 breast cancer cells. This type of MDR reflects cell/drain interaction upon the first clinical application of cancer chemotherapy.

The relatively high number of TICs required for this work was generated using the tumorigenesis approach based on anchorage-independent cell growth. This kind of cancer cell growth is known to favour the proliferation of TICs compared to regular monolayer growth [9]. MDR transport in TICs and bulk...
cells was estimated at the single cell level and characterized by the \( V_{\text{max}} \) and \( K_M \) parameters (we [10] and others [11] have previously shown a significant advantage of single-cell measurements over population-based measurements in kinetic studies). We found that activation of MDR transport in TICs, compared to transport in bulk cells, is highly heterogeneous and realized by two alternative mechanisms. These mechanisms are an elevation of MDR activity (\( V_{\text{max}} \)) in one subpopulation of TICs and an increase of MDR affinity (decrease of \( K_M \)) in another subpopulation. Potential consequences of these findings for cancer chemotherapy are discussed.

**Materials and Methods**

1. **Cell and tumorsphere culture conditions**

MCF-7 human and 4T1 murine breast cancer cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and grown in monolayers as recommended by ATTC. To generate tumorspheres, the floating (loosely adherent) cells were collected by washing ~70% confluent culture dishes with growth medium [12]. Collected floating cells were then cultured in ultralow attachment plates (Corning, Acton, MA, USA) under serum-free conditions using medium # 05621 with appropriate supplements developed by STEMCELL Technologies (Vancouver, BC, Canada).

2. **Tumorsphere formation efficiency assay**

Trypsinized monolayers and tumorspheres were plated onto a 96-well plate (200 cells/well, medium # 05621, STEMCELL Technologies, Vancouver), the number of spheres formed was counted in 5 days [9].

3. **Cell chemoresistance**

Cell chemoresistance was deduced from cell viability in the presence of an anticancer agent, that was determined using a standard colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) reduction assay [13]. As previously described [14], after a period of growth in 96-well plates (48 h at 37°C, 10,000 cells/well, with or without 30 nM doxorubicin), cells were supplemented with MTT (0.5 mg/mL) and incubated for 4 h. Redox activity in viable cells converted the oxidized form of MTT into the reduced formazan form. Formazan crystals were released from cells and dissolved using SDS (3% final content). Redox activity/cell viability was estimated from formazan absorbance measured at 550 nm and expressed as percentage of absorbance for the untreated control.

4. **Measurement of MDR transport in single cells by fluorescence kinetic microscopy**

MCF-7 cells grown to 50–60% confluence were supplemented with 10 µM glyburide (MDR inhibitor) and loaded with 5 µM fluorescein (MDR substrate) for 30 min at 37°C (with 4T1 cells calcein-AM was used as MDR substrate). The cells were then washed free of extracellular fluorescein and glyburide and placed in the KRB buffer (115 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl\(_2\), 1.2 mM MgCl\(_2\), 1.2 mM NaH\(_2\)PO\(_4\), 15 mM NaHCO\(_3\), 10 mM glucose, pH 7.4). The kinetics of fluorescein efflux were monitored with kinetic fluorescent microscopy and analysed by means of Cell Profiler (Broad Institute, Cambridge, MA) [15] and Origin (Microcal, Northampton, MA) software following an approach described in detail elsewhere [10,16]. Control for variation of cell volume during time-lapse measurement was performed using z-stacks taken before and after time-lapse acquisition. Stacks were analysed with Fluoview version 5 (Olympus, Tokyo, Japan) and ImageJ (NIH, Bethesda, MD) [17] software packages.

5. **Assessment of CD44/CD24 status of the cells**

After completing the MDR efflux assay, the cells were subjected to immunophenotyping (assessing quantity of CD44 and CD24 biomarkers) for discrimination between TICs and bulk cells within the cell population in a field of view. Immunostaining and imaging were based on the protocol described by Gupta et al. [18], except that FITC and PE/Cy5 were used as fluorescent labels instead of Alexa Fluor 488 and Alexa Fluor 555, respectively. Fluorescence images of fixed and antibody-treated cells were captured (with a fully open confocal aperture) using a confocal laser scanner FV300 (Olympus, Tokyo, Japan) at 530 and 665 nm. Between 4 to 9 scans were performed and averaged to improve the signal to noise ratio of the final image. Cell fluorescence intensities were quantitated, presented as 2-D plots and subjected to image-based cytometric analysis for separation of bulk and TIC subpopulations. To establish gates on the plots determining subpopulations characterized by high and low marker expression, we used the well known fact that an MCF-7 cell monolayer culture has null or negligible content of TICs [19,20].

6. **Toluidine blue cell staining**

Toluidine blue cell staining, used as an alternative cell sorting criterion, was performed according to a previously published protocol [12,21]. The staining intensity was estimated using an FV300 laser scanner in transmission mode.

7. **Flow cytometric measurements of MRP1 expression and plasma membrane permeability**

MRP1 expression was estimated using flow cytometry with FITC mouse anti-human MRP1 antibody QCRL-3 and appropriate isotype control (BD Biosciences, San Jose, CA, cat # 557593 and 555573, respectively) according to published procedure [22]. Results were analyzed ratiometrically as mean fluorescence with MRP1-specific antibody divided by mean fluorescence with isotype control [23]. Plasma membrane permeability was tested using two-color flow cytometric assay which estimates a cell’s ability to retain fluorescein derivative bis-carboxyethyl carboxy fluorescein (BCECF) and to exclude propidium iodide (PI) [24]. Measurements were performed using BD FACSCanto II Flow Cytometer.
Results

1. Tumorigenic and chemoresistant properties of monolayer and tumorsphere cells

First, we assessed tumorigenic potential (using its *in vitro* criterion anchorage-independent growth [25]) and chemoresistance of total cell populations derived from MCF-7 monolayers and tumorspheres. This was performed by determining the efficiency of tumorsphere formation and survival rate in the presence of an anticancer agent in both types of cells.

Monolayers (Figure 1a, left image) and tumorspheres (Figure 1a, right image) were dissociated and subjected to tumorsphere formation efficiency assay (see Materials and methods). Figure 1b indicates that cells originating from tumorspheres showed a significantly higher ability to undergo anchorage-independent growth compared to monolayer cells (*p* < 0.05, *n* = 3).

Overall estimation of chemoresistance in these types of cells was performed by comparison of the chemotherapeutic effect exerted by a low dose of doxorubicin on cells from dissociated tumorspheres and regular monolayers. Results shown in Figure 1c indicate better survival of the tumorsphere-derived cells compared to cells from monolayers in the presence of low dose doxorubicin (*p* < 0.05, *n* = 3).

Obviously improved survival of tumorsphere cells can be tentatively attributed to their increased multidrug resistance. We [10] and others [14,26] have previously shown that MCF-7 cells possess moderate intrinsic multidrug resistance of MRP-type. We therefore compared the expression of the MRP1, the most commonly encountered transporter of this type, in monolayers and tumorspheres. Comparative investigation showed somewhat higher MRP1 expression level in tumorspheres (Figure 1, d). However, MDR function is determined by many factors besides transporter expression, and poor and even negative correlation between expression and function of MDR transporters is not uncommon [27,28]. Therefore, functional evidence was required to understand the mechanisms of elevated chemoresistance in TICs.

As a preliminary precaution, we tested both cell types for plasma membrane permeability which might contribute to different transmembrane drug distribution in these cells. We applied the widely used analysis of plasma membrane permeability with complementary fluorescent probes [24], which assesses membrane permeability in terms of cell fractions showing dye retention (with the dye BCECF), dye exclusion (with PI dye) and intermediate fraction. Figure 1, e shows that these parameters in tumorspheres remain close to those in monolayer cells.

2. MDR efflux and estimation of functionally active MDR transporter content in naïve MCF-7 cells

Here we examined MDR efflux in MCF-7 cells belonging to the TIC or bulk subpopulations using fluorescence kinetic...
imaging. To allow for the possible photoinduced cell shrinkage, we tested stability of cell volumes in the course of time-lapse cell observation (see Materials and methods). It was determined that variation of cell volume during time series acquisition is below experimental error in cell volume estimation (9 %). The cells were loaded with fluorescein (substrate of MRP family of MDR transporters) and allowed to extrude it. The extrusion process was monitored by scanning fluorescent microscopy (Figure 2a), and kinetic description of MDR transport in single cells was derived as described in detail previously [10,16]. Naturally, this intrinsic activity is significantly lower than the induced activities of MRP and other types of transporters observed in cells exposed to different drugs [10]. For a rough estimate of the number of MDR transporter molecules driving this activity we used the average maximum rate of fluorescein efflux determined in this and previous work [10] \( V_{\text{max}} = 3 \text{nM/s} \) and a turnover number typical for ABC transporters [29] \( T/N = 10 \text{s}^{-1} \). Since \( V_{\text{max}} = T/N \times [\text{enzyme}]_{\text{total}} \), comparison of these values showed that the [enzyme]_{total} in this system is about 0.3 nM. Assuming the cell volume to be \( 2 \text{pL} \) [30] we estimated the cellular enzyme content to be below 1,000 molecules per cell. At such a low target level, accuracy of immunostaining can be compromised [27,31], which heightens the importance of functional MDR investigation.

3. MDR transport in MCF-7 tumorsphere-forming cells sorted by cell surface biomarker criterion

Breast cancer tumorspheres (mammospheres) are known to contain a significant fraction of TICs [9,32]. This property of tumorspheres allows us to get TIC-related information from monitoring MDR efflux in the whole cell population produced by dissociation of tumorspheres. After the completion of kinetic measurements, the cells were sorted into TIC and bulk cell subpopulations according to the expression levels of commonly used biomarkers CD44 and CD24. In order to combine kinetic and immunophenotype descriptions of individual cells we used microscopic (imaging) immunophenotyping instead of flow cytometry. This technique is finding increasing application in situations where flow cytometry is not sufficient [33-35]. Repetitive scanning of the cells immunostained after completion of the MDR assay (see Materials and methods for details) was followed by scan averaging for signal-to-noise ratio improvement. Resulting images (Figures 2b and 2c) closely resemble reported images of cells immunostained without a preceding MDR assay [18,36], suggesting no significant interference between the MDR assay and immunostaining. Fluorescence intensities of individual cells were organized and displayed as a 2D plot (Figure 2d).

Considering the lower right quadrant of the gated 2D plot (Figure 2d) as the TIC fraction, we compared frequency distributions of single-cell \( V_{\text{max}} \) and \( K_M \) values from this quadrant with the rest of the data (Figure 2e). It is clear that the CD44^{high}/CD24^{low} population is characterized by the right shift in \( V_{\text{max}} \) distribution and left shift in the distribution of \( K_M \). In fact, the distribution of \( V_{\text{max}} \) suggests the separation of the fraction of CD44^{high}/CD24^{low} cells having elevated \( V_{\text{max}} \) from the cells demonstrating slow transport. In the \( K_M \) distribution within CD44^{high}/CD24^{low} cells separation of cell fraction with high affinity from low affinity cells is less pronounced. However, the most populated (modal) bin in the CD44^{high}/CD24^{low} histogram was always the lowest one. In the bulk cell histograms the maximal bin was distant from the histogram edge. It is possible that the downward shift in the \( K_M \) distribution was partially masked by the general left skewed shape of these distributions. Interestingly, the alterations in \( V_{\text{max}} \) and \( K_M \) did not correlate with each other, thereby suggesting the existence within the whole CD44^{high}/CD24^{low} subpopulation of three types of cells: cells with decreased \( K_M \), cells with elevated \( V_{\text{max}} \), and cells remaining similar to those in the bulk tumor. A statistical summary of kinetic parameters characterizing TICs and bulk cells is shown in Figure 2, f.

We were also interested in determining the degree of \( V_{\text{max}} \) and \( K_M \) dispersion within TIC and bulk cell populations. Distributions of \( V_{\text{max}} \) and \( K_M \) parameters within these populations considerably deviate from normal (Figure 2, d, e; Figure 3, c, d), therefore we chose to characterize \( V_{\text{max}} \) and \( K_M \) dispersion using the robust coefficient of variation (rCV). rCV is the ratio of interquartile range which spans the central 50% of a data set, to the median value of a data set, which is more appropriate than common CV for description of skewed distributions [37]. Calculations showed that rCVs of \( V_{\text{max}} \) and \( K_M \) distributions of the TIC population were approximately 2-fold higher than those of the bulk population (data not shown).

4. MDR transport in MCF-7 tumorsphere-forming cells sorted by cell morphology criterion

Next we confirmed the acceleration of MDR kinetics in TICs using intensity of cellular staining with toluidine blue as an independent cell sorting criterion. Toluidine blue is a cationic dye whose intensity of staining reflects the degree of differentiation of mammary epithelial cells, so that pale staining corresponds to less differentiated cells (presumably stem cells and early progenitors) [12,21]. Figure 3.e shows that \( V_{\text{max}} \) and \( K_M \) of the bright (differentiated) and pale (undifferentiated) cells differ in such a way that undifferentiated cells demonstrate a higher rate and tighter affinity of MDR transport. However, using toluidine blue-based cell sorting we observed a general upward shift of the \( V_{\text{max}} \) distribution in pale cells rather than separation between fast and slow subpopulations.

5. MDR transport in 4T1 cell subpopulations tumorsphere-forming cells sorted by cell surface biomarker criterion

We examined the generality of kinetic MDR features found in TICs of MCF-7 cell line by studying MDR efflux in murine breast cancer cell line 4T1. This type of cells also forms tumorspheres with elevated expression of CD44^{high}/CD24^{low} phenotype [38] but shows mixed multidrug resistance of MDR and MRP types [39,40]. Therefore the kinetics of MDR efflux was measured with universal MDR substrate calcein [41] using cell array slides (Molecular Cytomix Inc., Boston, MA [42]), otherwise experimental protocol was similar to that used with MCF-7 cells.

Distribution of \( V_{\text{max}} \) and \( K_M \) values within bulk cells and TICs, as well as cumulative mean data are shown in Figure 4. Similarly to MCF-7 cells, TICs in 4T1 cell line show wider than...
bulk cells distribution of \( V_{\text{max}} \) values with increased mean value. Range of \( K_M \) variation in TICs is also broader than in bulk cells, but, in contrast to MCF-7 cells, \( K_M \) mean values in both subpopulations of 4T1 cells are close to each other. However, due to broadened variation range TIC in 4T1 line, like in MCF-7 line, contain a significant fraction of cells with increased affinity (reduced \( K_M \)). Thus, data on two cancer cell types suggest that MDR kinetics in TIC differ from these in bulk cells by: (i) broader variation of \( V_{\text{max}} \) and \( K_M \) parameters, (ii) increased \( V_{\text{max}} \) mean value, (iii) formation within TIC of a fraction of cells with elevated MDR affinity (reduced \( K_M \)).

Moreover, an important feature of TICs is diminished proportion of cells in G2/M phase due to slower progression of cell cycle [43,44]. We found recently that G2/M cells have greater \( V_{\text{max}} \) values of MDR flux compared to G1 cells [10]. Thus different rates of cell cycle in TICs and bulk cells can make observed difference in \( V_{\text{max}} \) smaller than it actually is.

Figure 2. Kinetic and immunophenotyping analysis of MCF-7 TICs and bulk cells: (a) images taken at 10 min intervals illustrate MDR efflux from cells loaded with fluorescein; (b) immunostaining of the same cells for CD44; (c) immunostaining of the same cells for CD24; (d) 2-D plots of the fluorescence intensity of CD44 and CD24 signals in monolayer- (left) and tumorsphere-derived cells (right); (e) histograms of distribution of Michaelis parameters within CD44\textsuperscript{high}/CD24\textsuperscript{low} cells (gray bars) and bulk cells (white bars) demonstrating two ways of MDR activation in TICs; (f) cumulative data summarizing Michaelis parameters in CD44\textsuperscript{high}/CD24\textsuperscript{low} cells (gray bars) and bulk cells (white bars) in 5 independent experiments (total 1089 cells, \( p < 0.01 \)).

doi: 10.1371/journal.pone.0079222.g002
Discussion

It has been previously shown that the fraction of CD44<sup>high</sup>/CD24<sup>low</sup> cells in tumorspheres is significantly elevated compared to classical monolayer cell cultures [32,45,46]. This fact solves the technical problems associated with rare cell studies [47]. Using cell preparations derived from tumorspheres allowed us to extract TIC single-cell kinetics of MDR transport from moderately large cell populations.

These results provide quantitative kinetic evidence supporting the concept of elevated MDR in TICs. Moreover, the application of the single-cell kinetics approach produces a more comprehensive description of the TIC chemoresistance capacity. It shows the MDR-related heterogeneity of TICs (CD44<sup>high</sup>/CD24<sup>low</sup> subpopulation) which consist of 3 types of cells: cells with elevated rate of MDR efflux, cells with elevated MDR affinity, and cells with bulk cell MDR parameters. It is apparent that modulation of MDR transport in TICs caused by expressionional and functional alterations in membrane transporters involves catalytic and binding effects [48].

According to a theoretical treatment of transmembrane drug equilibration, the kinetic definition of the degree of drug resistance (for low drug levels, typical for in vivo conditions) is given by: $R = 1 - \left(\frac{V_{\text{max}}}{PK_M}\right)$, where $P$ is drug permeability [49]. Thus both $V_{\text{max}}$ increase and $K_M$ decrease of the MDR transport improve a TIC’s drug resistance. At the same time, one can expect that changes in $V_{\text{max}}$ have more general character than changes in $K_M$. While altered $V_{\text{max}}$ ($V_{\text{max}} = k_{\text{cat}} \times [\text{transporter}]$) relates to a particular transporter, altered $K_M$ relates to a particular transporter/substrate combination and may change as the substrate changes. For instance, modulation of plasma membrane properties affects the affinity of MDR transporter for some substrates, but not for others [50]. Thus it is conceivable, that in some cases reduced MDR affinity compensates for increased MDR activity. This kind of effect might explain recent reports arguing against MDR activation in TICs [5,6].

Increased variation (rCV) of $V_{\text{max}}$ and $K_M$ in TICs shows that heterogeneity in TICs significantly exceeds that in bulk tumor cells. Phenotypic heterogeneity within cancer cell populations attracts significant attention as a clinically important parameter [51,52]. There is strong evidence that this heterogeneity has a dynamic nature and involves interconversion between different...
phenotypes due to fluctuations in the levels of cell constituents [52]. As applied to TIC populations in this work, this concept implies interconversions between TICs with high and low MDR capacity. It was recently suggested that such systems can be subjected to specific therapeutic approach [52]. According to this approach, drug doses intended for killing bulk cells can be efficient against TICs if drug application is synchronized with the kinetics of interconversion between TICs with high and low MDR.

Occurrence of a fraction of TICs with increased MDR affinity (decreased $K_v$) has not been reported previously, and clinically can be an additional mechanism for the positive selection of TICs during chemotherapy [7,8]. Preferential survival of TICs under chemotherapy is known to result from an overexpression of MDR transporters, i.e., increased MDR $V_{max}$. Our data show that in a certain range of concentrations of chemotherapeutic ($K_{M \text{ tic}} < [\text{chemotherapeutic}] < K_{M \text{ bulk cell}}$), MDR transporters in TICs with improved affinity will be better saturated with substrate than those in bulk cells. Thus, even without expressional effects, MDR transport and chemoresistance in TICs will exceed those in bulk cells. This difference provides an additional mechanism for the increase of TIC content in tumors subjected to chemotherapy.

Classical "side population" assay performed at a standard substrate load [53] provides a functional estimation of MDR transport but does not determine its affinity. In contrast, monitoring of the full kinetics of MDR transport in single cells provides estimates of both velocity and affinity of the process. This information would be useful for the rational design of therapeutic regimens, especially for prevention of tumor TIC enrichment during chemotherapy.

**Author Contributions**

Conceived and designed the experiments: BBY, SNK. Performed the experiments: VK. Analyzed the data: VK. Wrote the manuscript: VK.

**References**

1. Lee JT, Herlyn M (2007) Old disease, new culprit: tumor stem cells in cancer. J Cell Physiol 213: 603-609. doi:10.1002/jcp.21252. PubMed: 17786956.
2. Bansal N, Banerjee D (2009) Tumor initiating cells. Curr Pharm Biotechnol 10: 192-196. doi:10.2174/13892010978751015. PubMed: 19199951.
3. Bernaudin JF, Fajac A, Fleury-Feith J, Kerrou K, Lacave R (2009) ABC Proteins and Oncology: Expression, Detection, and Implication of ABC Proteins in Solid Tumors. In: A Bournajel J Bouttonat J Robert. ABC Proteins in Solid Tumors. Hoboken: John Wiley & Sons. pp. 143-176.
4. Wu C, Alman BA (2008) Side population cell populations in human cancers. Cancer Lett 268: 1-9. doi:10.1016/j.canlet.2008.03.048. PubMed: 18487012.
5. Aulmann S, Waldburger N, Penzel R, Andrus M, Schirmacher P et al. (2010) Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum Pathol 41: 574-581. doi:10.1016/j.humpath.2009.08.023. PubMed: 20004947.
6. Yan H, Chen X, Zhang Q, Qin J, Li H et al. (2011) Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLOS ONE 6: e24397. doi:10.1371/journal.pone.0024397. PubMed: 21935404.
7. Yu Y, Yao H, Zhu P, Zhang X, Pan Q et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123. doi:10.1016/j.cell.2007.10.054. PubMed: 18083101.
8. Lacerta L, Puszta L, Woodward WA (2010) The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist Update 13: 99-108. doi:10.1016/j.drup.2010.08.001. PubMed: 20739212.
9. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511. doi:10.1158/0008-5472.CAN-05-0626. PubMed: 15994492.
10. Koshkin V, Krylov SN (2012) Correlation between multi-drug resistance-associated membrane transport in clonal cancer cells and the cell cycle phase. PLOS ONE 7: e41365. doi:10.1371/journal.pone.0041365. PubMed: 22848474.
11. Wong VW, Tsai TY, Liao JC (2007) Single-cell zeroth-order protein degradation enhances the robustness of synthetic oscillators. Mol Syst Biol 3: 130. PubMed: 17667952.
12. Ciocca M, Gherardi S, Viglietto G, Strano S, Blandino G et al. (2010) Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like and early progenitor-targeting drugs. Cell Cycle 9: 2878-2887. PubMed: 20581442.
13. Sumantran VN (2011) Cellular chemosensitivity assays: an overview. Methods Mol Biol 731: 219-236. doi:10.1007/978-1-61779-080-5_19. PubMed: 21514411.
14. Kans MD, Iserte OD, Gunduz U, Ural AU, Arpaci F et al. (2006) Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26: 4559-4568. PubMed: 17201178.
15. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH et al. (2006) CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7: R100. doi:10.1186/gb-2006-7-10-r100. PubMed: 17076895.
16. Koshkin V, Krylov SN (2011) Single-cell-kinetics approach to compare multidrug resistance-associated membrane transport in subpopulations of cells. Anal Chem 83: 6132-6134. doi:10.1021/ac201689t. PubMed: 21770449.
17. Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image Processing with ImageJ. Biophotonics Int 11: 36-42.
18. Gupta V, Zhang QJ, Liu YY (2011) Evaluation of anticancer agents using flow cytometry analysis of cancer stem cells. Methods Mol Biol 716: 179-191. doi:10.1007/978-1-61779-012-6_11. PubMed: 21318907.
19. Vesuna F, Lisic A, Kimble B, Raman V (2009) Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11: 1318-1328. PubMed: 19019840.
20. Zhan JF, Wu LP, Chen LH, Yuan YW, Xie GZ et al. (2011) Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation. Cell Oncol (Dordr) 34: 451-456.
21. Chepko G, Smith GH (1997) Three division-competent, structurally-distinct cell populations contribute to murine mammary epithelial renewal. Tissue Cell 29: 239-253. doi:10.1016/S0040-8166(97)80024-9. PubMed: 9149446.
22. Morris CJ, Peklak-Scott C, Bishowkarma B, Kute TE, Smitherman PK et al. (2006) Multidrug resistance protein 1 (MRP1, ABCB1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 69: 1499-1505. doi:10.1124/mol.05.107988. PubMed: 16434616.
23. Pallis M, Das-Gupta E (2005) Flow cytometric measurement of functional and phenotypic p-glycoprotein. In: RD Blumenthal. Chemosensitivity, vol. 2, vol. 111. Methods in molecular medicine. Totowa, NJ: Humana Press Inc., p. 167.
24. Dive C, Watson JV, Workman P (1990) Multiparametric analysis of cell membrane permeability by two colour flow cytometry with complementary fluorescent probes. Cytometry A 11: 244-252. doi:10.1002/cty.990110205. PubMed: 2318081.
25. Finlay TH, Tamir S, Kadner SS, Cruz MR, Yavelow J et al. (1993) alpha 1-antitrypsin- and anchorage-independent growth of MCF-7 breast cancer cells. Endocrinology 133: 996-1002. doi:10.1210/en.133.3.996. PubMed: 8365378.
26. Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL et al. (2009) Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not p-glycoprotein. Pharm Res 26: 914-925. doi:10.1007/s11095-009-9795-y. PubMed: 19067124.
27. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR et al. (1995) Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-eflux+ and MDR- efllux-cases. Blood 86: 2329-2342. PubMed: 7545025.

28. Lebedeva IV, Pande P, Patton WF (2011) Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLOS ONE 6: e22249. doi:10.1371/journal.pone.0022429. PubMed: 21799851.

29. Gorbulev S, Abele R, Tampe R (2001) Allosteric crosstalk between peptide-binding, transport, and ATP hydrolysis of the ABC transporter TAP. Proc Natl Acad Sci USA 98: 3732–3737. doi:10.1073/pnas.061467898. PubMed: 11274390.

30. Leung E, Kannan N, Krisannen GW, Findlay MP, Baguley BC (2010) MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9: 717-724. doi:10.4161/cbt.9.9.11432. PubMed: 20234184.

31. Taylor BJ, Olson DP, Ivy SP (2001) Detection of P-glycoprotein cell lines and leukemia blasts: failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells. Leuk Res 25: 1127-1135. doi:10.1016/S0145-2126(01)00085-6. PubMed: 11684287.

32. Guttilla IK, Phoenix KN, Hong X, Timauer JS, Claeyfy KP et al. (2012) Prolonged mammamsphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 132: 75-85. doi:10.1007/s10549-011-1534-y. PubMed: 21553120.

33. Chan LL, Zhong X, Qiu J, Li PY, Lin B (2011) Cellometer vision as an alternative to flow cytometry for cell cycle analysis, mitochondrial potential, and immunophenotyping. Cytometry A 79: 507-517. PubMed: 21538841.

34. Goodale D, Phay C, Postenka CO, Keeney M, Allan AL (2009) Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry A 75: 344-355. PubMed: 18855920.

35. Oswald J, Jørgensen B, Pompe T, Kobe F, Salchert K et al. (2004) Characterization of tumor cell dissemination in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry A 57: 100-107. PubMed: 14750131.

36. Theodoropoulos PA, Pololoudaki H, Agelaki S, Kallergi G, Sandaki Z et al. (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 289: 99-106. doi:10.1016/j.canlet.2009.06.027. PubMed: 19619935.

37. Shapiro HM (2005). Practical flow cytometry. 4th ed. Hoboken: John Wiley & Sons. 236 pp.

38. Yang X, Sarvestani SK, Moezinzedeh S, He X, Jabbari E (2013) Effect of CD44 binding peptide conjugated to an engineered inert matrix on maintenance of breast cancer stem cells and tumoursphere formation. PLOS ONE 8: e59147. doi:10.1371/journal.pone.0059147. PubMed: 23527117.

39. Zhao L, Jin X, Xu Y, Guo Y, Liang R et al. (2010) Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1. J Exp Clin Cancer Res 29: 98. doi:10.1186/1756-9966-29-98. PubMed: 20462825.

40. Zhao L, Sun Y, Li X, Jin X, Xu Y et al. (2011) Multidrug resistance strength of the novel multidrug resistance gene HA117 compared with MRP1. Med Oncol 28: 1188-1195. doi:10.1007/s12032-010-9624-y. PubMed: 20536168.

41. Karász E, Jakab K, Homolya L, Szakács G, Holló Z et al. (2001) Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukemia. Br J Haematol 112: 308-314. doi:10.1046/j.1365-2141.2001.02559.x. PubMed: 11167823.

42. Afrimzon I, Zurgil N, Shafraian Y, Leibovich P, Sobolev M et al. (2013) The use of sequential staining for detection of heterogeneous intracellular response of individual Jurkat cells to lysophosphatidylcholine. J Immunol Methods 387: 96-106. doi:10.1016/j.jim.2012.10.001. PubMed: 23063692.

43. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M (2010) Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 12: R31. doi:10.1186/bcr2684. PubMed: 20525204.

44. Yang ZL, Cheng K, Han ZD (2012) Effect of bFGF on the MCF-7 cell cycle with CD44(+) / CD24(-): promoting the G0/G1→G2/S transition. Breast Cancer 15: 388-392. doi:10.4048/jbc.2012.15.4.388.

45. Wang H, Huang M, Zhang DY, Zhang F (2011) Global profiling of signaling networks: study of breast cancer stem cells and potential regulation. Oncologist 16: 966-979. doi:10.1634/theoncologist.2010-0230. PubMed: 21665913.

46. Xue G, Zhan J, Tian Y, Liu Y, Chen Z et al. (2012) Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radiosensitivity. Cancer Lett 316: 53-61. doi:10.1016/j.canlet.2011.10.018. PubMed: 22108532.

47. Leary JP (1994) Strategies for Rare Cell Detection and Isolation. Methods Cell Biol 42: 331–358. doi:10.1016/S0091-679X(08)61083-3. PubMed: 7877504.

48. Picth DL (2010) Enzyme kinetics: catalysis & control. Amsterdam: Elsevier-AP. 382 pp.

49. Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77: 545-590. PubMed: 9114823.

50. Eckford PD, Sharom FJ (2008) Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47: 13666-13698. doi:10.1021/bi801409r. PubMed: 19049391.

51. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633-644. doi:10.1016/j.cell.2011.07.026. PubMed: 21854987.

52. Liao D, Estévez-Salmerón L, Tlsty TD (2012) Conceptualizing a tool to optimize therapy based on dynamic heterogeneity. Phys Biol 9: 065005. doi:10.1088/1478-3975/9/6/065005. PubMed: 22197079.

53. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP (2011) Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 8: 136-147. doi:10.1016/j.stem.2011.01.007. PubMed: 21295271.